A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas
This study has been completed.
Sponsor:
Pharmacyclics
Information provided by:
Pharmacyclics
ClinicalTrials.gov Identifier:
NCT00080054
First received: March 22, 2004
Last updated: April 2, 2009
Last verified: January 2007
Tracking Information | |
---|---|
First Received Date ICMJE | March 22, 2004 |
Last Updated Date | April 2, 2009 |
Start Date ICMJE | |
Primary Completion Date | |
Current Primary Outcome Measures ICMJE | |
Original Primary Outcome Measures ICMJE | |
Change History | Complete list of historical versions of study NCT00080054 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures ICMJE | |
Original Secondary Outcome Measures ICMJE | |
Current Other Outcome Measures ICMJE | |
Original Other Outcome Measures ICMJE | |
Descriptive Information | |
Brief Title ICMJE | A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas |
Official Title ICMJE | Phase I Trial of Motexafin Gadolinium (MGd) in Combination With Temozolomide for Treatment of Malignant Gliomas |
Brief Summary | The purpose of this study is to find out about the safety of adding the investigational drug motexafin gadolinium to a standard course of chemotherapy with temozolomide for patients with malignant glioma. Secondly, the study will determine how many patients will respond to this treatment. |
Detailed Description | |
Study Type ICMJE | Interventional |
Study Phase | Phase 1 |
Study Design ICMJE | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Condition ICMJE |
|
Intervention ICMJE | Drug: Motexafin Gadolinium Injection |
Study Arm (s) | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
Recruitment Information | |
Recruitment Status ICMJE | Completed |
Enrollment ICMJE | 24 |
Completion Date | |
Primary Completion Date | |
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria: Laboratory values of:
and
|
Gender | Both |
Ages | 18 Years and older |
Accepts Healthy Volunteers | No |
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects |
Location Countries ICMJE | United States |
Administrative Information | |
NCT Number ICMJE | NCT00080054 |
Other Study ID Numbers ICMJE | PCYC-0218 |
Has Data Monitoring Committee | |
Responsible Party | |
Study Sponsor ICMJE | Pharmacyclics |
Collaborators ICMJE | |
Investigators ICMJE | |
Information Provided By | Pharmacyclics |
Verification Date | January 2007 |
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |